Yourgene Elucigene DPYD

Sep 18, 2019

UK-based Yourgene has launched the Elucigene DPYD assay, a CE-marked chemotoxicity diagnostic test that uses genotyping to identify cancer patients with dihydropyrimidine dehydrogenase (DPD) deficiency. The deficiency causes several and sometimes lethal side effects in patients treated with 5-fluorouracil (5-FU), which is metabolized by the DPD enzyme, encoded by the DPYD gene. Elucigene DPYD, which tests for six common genetic variations, conforms with Clinical Pharmacogenetics Consortium guidelines, which recommend testing for four clinically relevant mutations.

Yourgene Elucigene DPYD

WHO Approves Abbott Molecular Mpox Assay

Foresight Diagnostics Founders Respond to Roche Lawsuit, Says Claims Asserted in Bad Faith

Participant Health Privacy at Risk From Single-Cell RNA Sequencing Data, Study Suggests

With $40M in Funding, Cancer AI Alliance Aims to Pool Data, Computing Resources to Boost Research

Oncocyte Nets $10.2M in Private Placement, Notes New Customers for Transplant Test